<?xml version='1.0' encoding='utf-8'?>
<document id="29776316"><sentence text="A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone."><entity charOffset="90-102" id="DDI-PubMed.29776316.s1.e0" text="paliperidone" /></sentence><sentence text="This article includes a combined analysis of therapeutic drug monitoring (TDM) studies and a review of the marketer's data on pharmacological mechanisms" /><sentence text=" Areas covered: An article search led to the inclusion of 21 paliperidone studies in the systematic review plus 2 case reports" /><sentence text=" Paliperidone clearance was calculated from: 1) steady-state studies using concentration/dose (C/D) ratios, and 2) single-dose studies describing 24-h area under the curve calculations"><entity charOffset="1-13" id="DDI-PubMed.29776316.s4.e0" text="Paliperidone" /></sentence><sentence text=" The marketed extended-release formulation has 28% bioavailability" /><sentence text=" Calculated mean C/D ratios (ng/ml/mg/d) were: 1) 4" /><sentence text="09 in 6 studies of 221 non-Korean and non-geriatric adult patients, 2) 2" /><sentence text="59 in 2 studies of 100 Korean adult patients, and 3) 6" /><sentence text="89 in 1 study with 15 elderly Japanese patients" /><sentence text=" The limited drug-drug interaction studies indicated that carbamazepine is a clinically relevant inducer requiring three times the dosage, and that valproate, probably an inhibitor, requires half the dosage"><entity charOffset="58-71" id="DDI-PubMed.29776316.s10.e0" text="carbamazepine" /><entity charOffset="148-157" id="DDI-PubMed.29776316.s10.e1" text="valproate" /><pair ddi="false" e1="DDI-PubMed.29776316.s10.e0" e2="DDI-PubMed.29776316.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29776316.s10.e0" e2="DDI-PubMed.29776316.s10.e1" /></sentence><sentence text=" Renal impairment markedly decreased paliperidone elimination, and other antipsychotics should be considered"><entity charOffset="37-49" id="DDI-PubMed.29776316.s11.e0" text="paliperidone" /></sentence><sentence text=" Expert Commentary: We recommend more use of: 1) paliperidone TDM in clinical practice, 2) TDM when moving from oral to long-acting paliperidone, 3) better designs for paliperidone TDM studies, 4) laboratory studies on paliperidone pharmacokinetic mechanisms, and 5) TDM studies comparing paliperidone and risperidone dosing"><entity charOffset="132-144" id="DDI-PubMed.29776316.s12.e0" text="paliperidone" /><entity charOffset="168-180" id="DDI-PubMed.29776316.s12.e1" text="paliperidone" /><entity charOffset="219-231" id="DDI-PubMed.29776316.s12.e2" text="paliperidone" /><entity charOffset="289-301" id="DDI-PubMed.29776316.s12.e3" text="paliperidone" /><entity charOffset="306-317" id="DDI-PubMed.29776316.s12.e4" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e0" e2="DDI-PubMed.29776316.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e0" e2="DDI-PubMed.29776316.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e0" e2="DDI-PubMed.29776316.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e0" e2="DDI-PubMed.29776316.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e0" e2="DDI-PubMed.29776316.s12.e4" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e1" e2="DDI-PubMed.29776316.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e1" e2="DDI-PubMed.29776316.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e1" e2="DDI-PubMed.29776316.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e1" e2="DDI-PubMed.29776316.s12.e4" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e2" e2="DDI-PubMed.29776316.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e2" e2="DDI-PubMed.29776316.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e2" e2="DDI-PubMed.29776316.s12.e4" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e3" e2="DDI-PubMed.29776316.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29776316.s12.e3" e2="DDI-PubMed.29776316.s12.e4" /></sentence><sentence text="" /></document>